Uncategorized

JOSD1 Drives Hepatocellular Carcinoma Malignancy by Modulating the Ubiquitination-Lactylation Switch on PGAM1

[Gut] Researchers elucidated the function of the deubiquitinase JOSD1 in modulating post-translational modification crosstalk and its impact on tumour glycolysis, progression, and immunotherapy response in HCC.

FXR-YAP Signalling Maintains Biliary Epithelial Cell Identity and Preserves Liver Homeostasis

[Nature Metabolism] Investigators showed that biliary epithelial cells safeguard biliary barrier integrity and restrain bile acid-induced fibrogenesis through a cell-intrinsic mechanism involving farnesoid-X-receptor (FXR)–YAP signaling.

Targeting of the Nuclear RNA Exosome to Chromatin by HP1 Affects the Transcriptional Programs of Liver Cells

[Nature Communications] The authors uncovered a direct interaction between heterochromatin protein 1 (HP1) and nuclear RNA exosome complexes, major RNA decay machineries.

Mitochondrial Fusion Heterogeneity Drives Bidirectional Tumor Phenotypic Transition in Combined Hepatocellular-Cholangiocarcinoma

[Proceedings of the National Academy of Sciences of the United States of America] Scientists induced mosaic impairment of mitochondrial fusion in mouse liver under tumorigenic conditions and unexpectedly identified the formation of combined hepatocellular-cholangiocarcinoma, a monoclonal tumor displaying features of both HCC and intrahepatic cholangiocarcinoma.

AURKA Suppresses NCOA4-Mediated Ferritinophagy to Enhance Sorafenib Resistance in Hepatocellular Carcinoma

[Cell Death & Disease] Researchers identified Aurora Kinase A (AURKA) as a central, actionable regulator of ferroptosis resistance in sorafenib-resistant HCC.

Vitamin D Receptor Isoform VDRA Suppresses Hepatocellular Tumorigenesis by Restricting YAP Nuclear Localization

[Cell Death & Disease] Investigators demonstrated that 1,25(OH)2D3 induced coordinate expression of both vitamin D receptor isoforms in HCC cells, activated divergent transcriptional programs, particularly concerning the regulation of yes-associated protein (YAP) target genes.

SIAH2-EPHB6 Axis Enhances Filopodia Formation in Hepatocellular Carcinoma Cells by Regulating RHOF

[Cell & Bioscience] The authors demonstrated that seven in absentia homologue 2 (SIAH2) accelerates the invasion and migration of HCC cells by promoting K48-linked polyubiquitination and degradation of EPH receptor B6 (EPHB6).

METTL1-Mediated m7g Modification of ASNS mRNA Regulates Asparagine Metabolism Reprogramming to Promote Hepatocellular Carcinoma Progression

[Oncogene] Scientists identified that METTL1 was significantly upregulated in HCC tissues, correlating with advanced stages and poor survival.

Spermidine Suppresses Liver Fibrosis by Remodeling the Communication Signal between Liver Sinusoidal Endothelial Cells and Hepatic Stellate Cells

[Cell Death Discovery] Analysis of NHANES data revealed an inverse association between dietary spermidine (SPD) intake and fibrosis risk. Consistently, in vivo and in vitro models demonstrated that SPD significantly ameliorated liver sinusoidal endothelial cells dysfunction and attenuated fibrosis progression.

SNAP23 Regulates CPEB4 in the Autophagy of Hepatocellular Carcinoma

[Scientific Reports] Researchers investigated the roles of SNAP23 and CPEB4 in HCC progression and the underlying molecular mechanisms. Using bioinformatics analysis and in vitro experiments in Huh7 cells, they found that SNAP23 was upregulated in HCC and positively correlated with CPEB4.

NF-κB Signaling in Hepatocellular Carcinoma: Mechanisms of Tumor Progression, Immune Evasion, and Therapeutic Resistance

[Translational Oncology] Investigators synthesize recent mechanistic and translational advances that redefine NF-κB as a central adaptive program in HCC and further discuss the clinical implications of NF-κB signaling for tumor stratification and therapeutic intervention.

TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors

[TriSalus Life Sciences, Inc.] TriSalus Life Sciences, Inc., announced the initiation of patient enrollment for the PREDICTT clinical trial (NCT07444645), a prospective study designed to evaluate its novel Pressure-Enabled Drug Delivery™ (PEDD™) approach in patients with primary or metastatic liver tumors.
spot_img